Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

· manilatimes.net

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027

Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027

NDA resubmission activities for ZYNQUISTA® in type 1 diabetes nearing completi...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI